CoChat

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimumab as 2nd line therapy in elderly ESCC patients. METHODS: RAMONA is a multicenter open-label phase II trial. The primary objective is to demonstrate a significant survival benefit of nivolumab/ipilimumab in advanced ESCC compared to historical data of standard chemotherapy. Primary endpoint is therefore overall survival (OS). Major secondary objective is the evaluation of tolerability. Time to QoL deterioration will thus be determined as key secondary endpoint. Further secondary endpoints are tumor response, PFS and safety. We aim to recruit a total of n = 75 subjects that have to be > 65 years old. Eligibility is determined by the geriatric status (G8 screening and Deficit Accumulation Frailty Index (DAFI)). A safety assessment will be performed after a 3 cycle run-in phase of nivolumab (240 mg Q2W) to justify escalation for eligible patients to combined nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W), while the other patients will remain on nivolumab only. RAMONA also includes translational research sub-studies to identify predictive biomarkers, including PD-1 and PD-L1 evaluation at different time points, establishment of organoid cultures and microbiome analyses for response prediction. DISCUSSION: The RAMONA trial aims to implement checkpoint inhibitors for elderly patients with advanced ESCC as second line therapy. Novel biomarkers for checkpoint-inhibitor response are analyzed in extensive translational sub-studies. TRIAL REGISTRATION: EudraCT Number: 2017-002056-86 ; NCT03416244 , registered: 31.1.2018.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-019-5446-2

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study scheme. Patients may be escalated to nivolumab/ipilimumab combination therapy after a 3 cycle nivolumab-only run-in phase and positive safety assessment. GA: geriatric assessment (G8 / DAFI). ***: treatment escalation according to safety assessment results (please see full protocol). **: Chemotherapy (+/− radiotherapy) (e.g. CROSS, FLOT or similar protocols) OR any palliative systemic chemotherapy. * Stage 4 OR stage 3 non-responder to radio-chemotherapy OR any relapse after chemo-radiation OR any relapse after surgery if patient is ineligible or intolerant to standard frontline therapy OR refuses other treatment. PD1: off study despite post-progression ipi/nivo in case of toxicity and/or clinical deterioration. PD2: off study if confirmed progression according to Recist criteria V 1.1 or non-response according to immune-related response criteria. Ipilimumab 1 mg/kg IV Q6W. Nivolumab 240 mg IV Q2W. Restaging (incl. Endoscopic biopsies +PD-L1 staining)
Fig. 1 Study scheme. Patients may be escalated to nivolumab/ipilimumab combination therapy after a 3 cycle nivolumab-only run-in phase and positive safety assessment. GA: geriatric assessment (G8 / DAFI). ***: treatment escalation according to safety assessment results (please see full protocol). **: Chemotherapy (+/− radiotherapy) (e.g. CROSS, FLOT or similar protocols) OR any palliative systemic chemotherapy. * Stage 4 OR stage 3 non-responder to radio-chemotherapy OR any relapse after chemo-radiation OR any relapse after surgery if patient is ineligible or intolerant to standard frontline therapy OR refuses other treatment. PD1: off study despite post-progression ipi/nivo in case of toxicity and/or clinical deterioration. PD2: off study if confirmed progression according to Recist criteria V 1.1 or non-response according to immune-related response criteria. Ipilimumab 1 mg/kg IV Q6W. Nivolumab 240 mg IV Q2W. Restaging (incl. Endoscopic biopsies +PD-L1 staining)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 30

Metadata

Authors
Meindl-Beinker, N. M., Betge, J., Gutting, T., Burgermeister, E., Belle, S., Zhan, T., Schulte, N., Maenz, M., Ebert, M. P., & Haertel, N.
Affiliations
  • Heidelberg University (DE)
  • AIO Studien gGmbH (DE)
Venue
BMC Cancer
Published
2019-03-14
Volume
19
Issue
1
Pages
231-231
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2936810997
Cited by
30
References
35
Citations by year
2025: 3 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 3
FWCI
1.98
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • heiDOK (Heidelberg University) (acceptedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • sponsored by AIO-Studien gGmbH funded by BMS (AIO-STO-0117)
  • grants from the State of Baden-Württemberg for “Center of Geriatric Biology and Oncology (ZOBEL) - Perspektivförderung
  • grants from the State of Baden-Württemberg for “Biology of Frailty - Sonderlinie Medizin”
  • Medical Faculty Mannheim and the State of Baden-Württemberg
  • Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and Arts and by Ruprecht-Karls-Universität Heidelberg
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
esophageal squamous cell carcinoma, nivolumab, ipilimumab, immune checkpoint inhibitors, second-line therapy, elderly patients, overall survival, frailty, geriatric assessment, PD-1, PD-L1, predictive biomarkers, microbiome, organoid culture, quality of life
MeSH terms
Ipilimumab, Nivolumab, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Esophageal Neoplasms, Humans, Survival Analysis, Treatment Outcome, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). https://app.cochat.ai/papers/10.1186/s12885-019-5446-2
The paper
Meindl-Beinker, N. M., Betge, J., Gutting, T., Burgermeister, E., Belle, S., Zhan, T., Schulte, N., Maenz, M., Ebert, M. P., & Haertel, N. (2019). A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). BMC Cancer. https://doi.org/10.1186/s12885-019-5446-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.